Navigation Links
Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
Date:9/9/2008

cer of the Canadian Medical Discoveries Fund, a biotech venture capital fund. Dr. Stiller has authored more than 265 medical and scientific papers and has received a significant number of awards throughout his career for his medical contributions and entrepreneurship. Additionally, he has co-founded many organizations and programs including the Ontario Institute for Cancer Research.

In welcoming Dr. Stiller to Jennerex' board, Chairman Brennan Mulcahy commented that, "Dr. Stiller brings a wealth of medical and biotech experience to Jennerex, as well as extensive experience with emerging biotech companies. As Jennerex develops its corporate structure to support its clinical trials program, Dr. Stiller's counsel will be invaluable in guiding the board and management through a critical period in the company's development."

"I am excited to join the board of Jennerex at this exciting stage of its development," said Dr. Stiller. "The JX-594 lead product, as well as other offerings in this product class, have great potential to change cancer care and to develop significant market penetration for these novel therapeutics. I am very impressed with the Jennerex team which has made huge progress to date in a relatively short time, and with great efficiency in use of capital," added Dr. Stiller.

About JX-594

JX-594 is a cancer biotherapeutic, currently in Phase II trials, from a proprietary breakthrough class of targeted and armed oncolytic poxviruses. Tumor destruction and safety was shown in patients with diverse cancer types in three Phase I trials; treated patients were end-stage and had no effective therapies available. JX-594 multiplies selectively within cancer cells, leading to their destruction. These newly created copies of JX-594 are then released and are able to infect and eradicate other tumor cells both locally and in distant sites in the body. This cycle of JX-594 replication, cancer cell destruction, release and spread is then repeat
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy
2. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
3. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
4. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
5. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
6. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
7. Renowned NJ-Based Video Assisted Thoracic Surgery (VATS) Team Completes 5,000th Successful Procedure
8. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
9. Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round
10. NuVasive Completes Acquisition of Osteocel Biologics Business
11. Hologic Completes Cash Tender Offer for Third Wave Technologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Raleigh, NC (PRWEB) June 19, 2013 ... and eclinical commerce network for clinical trials, today ... technology at DIA 2013 (booth #2000) in Boston, ... is the industry’s first and only fully configurable, ... technology, ClinPay®, the flagship module within Clinverse’s eClinical ...
(Date:6/19/2013)... 19, 2013  Continuing its long history of proven ... Beckman Coulter , Inc. announces the U.S. Food and ... AccuTnI+3 troponin I assay for use on its Access ... on Beckman Coulter,s troponin I test for ... the proven performance to continue providing dependability to laboratories ...
(Date:6/19/2013)... 2013 Today DuPont Executive Vice President ... become leaders in the greatest challenge facing our time ... 2050. Borel spoke at the International Food ... about urgent need for students to contribute their time ... sustainable and reached in collaboration with others. , “Food ...
(Date:6/19/2013)... Bloomington, Indiana (PRWEB) June 19, 2013 ... Valentine joined the speaking faculty at 2013’s BioLogistics ... , The conference, coordinated by Cold Chain IQ ... surrounding biologics. This “complexity” is, in part, attributed ... medicine. , “Implicit within these trends is ...
Breaking Biology Technology:Clinverse, Inc. Exhibiting and Showcasing Its Technology at DIA 2013 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 3DuPont Leader Calls for New Generation of Food Visionaries to Fight Hunger 2BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2
... Chindex International,Inc. (Nasdaq: CHDX ), an independent ... products in the People,s,Republic of China, today announced ... ended March 31, 2008., For the 2008 ... $130.1,million, an increase of 23% over the prior ...
... Takes Prominent Position and ... WEST SENECA, N.Y., June 11 Palladian Muscular Skeletal,Health ... a high-profile presence at a leading healthcare event -- ... June,18 to Friday, June 20, 2008., "We have ...
... Rosetta Genomics has Signed a Binding Term Sheet to Acquire Parkway ... ... Significantly Streamline the Development and Commercialization of Rosetta Genomics, microRNA-based ... Needs to Market and Sell its microRNA-based Tests in the U.S. and ...
Cached Biology Technology:Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 2Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 3Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 4Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 5Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 6Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 7Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 8Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 9Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results 10Palladian Muscular Skeletal Health (formerly Prism Health Networks) to Promote Collaborative, Expanded Practice Model at Major Insurance Conference in June 2Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 2Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 3Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 4Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 5Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests 6
(Date:6/19/2013)... June 19, 2013 A study published in the ... the first report of an oral probiotic supplement significantly ... , The lead author on the study, Mitchell ... Presentation Prize from the New York Academy of Sciences ... week,s Probiotics, Prebiotics, and the Host Microbiome: The ...
(Date:6/19/2013)... the Marine Biological Laboratory (MBL), Woods Hole, Massachusetts, ... by the American Society for Microbiology (ASM). ... and the scientists who worked there that have ... microbiology. A ceremony unveiling the plaque that ... June 22, 2013, at 4:30 pm in the ...
(Date:6/19/2013)... A team of researchers at the University of ... outer coating of HIV, that could be potential ... avoid generating resistance. These new agents are quite ... The research was published in the June 2013 ... Chemotherapy . , The first of many probable ...
Breaking Biology News(10 mins):Study shows probiotic Lactobacillus reuteri NCIMB 30242 significantly increased vitamin D levels 2Microbial diversity course designated as a 'Milestones in Microbiology' site 2HIV-derived antibacterial shows promise against drug-resistant bacteria 2
... under scrutiny lately due to adverse cardiovascular side-effects stemming ... models, researchers reveal another adverse effect of Celecoxib; this ... independent of the COX-2 enzyme. Satpal Singh ... rate of Drosophila, a good model for human cardiac ...
... friends used to think he was eccentric, crawling like ... Pennsylvania, hauling dental tools and a jack hammer. ... gotten over it, and are congratulating him on receiving ... Society, presented at the Geological Society of Americas recent ...
... of medical and scientific books and journals, was ... content is immediately available on www.springerlink.com ... and more than 22,000 eBooks. Beginning with the ... purchase Humana Press journals through Springer. All issues ...
Cached Biology News:Academy volunteer wins national paleontology award 2Humana Press journals now available on SpringerLink 2
... Rabbit polyclonal to Taura ... Abpromise for all tested ... Synthetic peptide: VTNSEGSTIL MNDIPITNQN ... ATEFNQ, corresponding to N terminal ...
Goat polyclonal to SART3 ( Abpromise for all tested applications). Antigen: Synthetic peptide: MSNADFAKLFLRK, corresponding to C terminal amino acids 951-963 of Human SART3 Entrez Gene ID: 9...
... Immunogen: KLH-conjugated, synthetic peptide ... which [ Ac K] corresponds to acetyl ... Accession Number: NM_003493 ... Quality Assurance: Routinely ...
Blank Calibration Particles, 3.0-3.4 mu m 5 ml...
Biology Products: